Roll out of intraveneous artesunate under named patient programmes in the Netherlands, Belgium and France

BACKGROUND: Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, this treatment is only available in a few countries via named patient programmes (NPPs). As a case study, the legal and organisational aspects and pharmacovigilance of these NPPs and possibilities for h...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreeftmeijer-Vegter, Annemarie Rosan, van Veldhuizen, Cornelis KW, de Vries, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848968/
https://www.ncbi.nlm.nih.gov/pubmed/24063858
http://dx.doi.org/10.1186/1750-1172-8-150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848968/
https://www.ncbi.nlm.nih.gov/pubmed/24063858
http://dx.doi.org/10.1186/1750-1172-8-150

Ejemplares similares